Unresectable Gastroesophageal Junction Adenocarcinoma Recruiting Phase 1 Trials for Ceralasertib (DB14917)

IndicationStatusPhase
DBCOND0113409 (Unresectable Gastroesophageal Junction Adenocarcinoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04704661Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialTreatment